<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401035</url>
  </required_header>
  <id_info>
    <org_study_id>B1791089</org_study_id>
    <secondary_id>2014-002182-29</secondary_id>
    <secondary_id>B1791089</secondary_id>
    <secondary_id>GERD</secondary_id>
    <nct_id>NCT02401035</nct_id>
  </id_info>
  <brief_title>PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects</brief_title>
  <official_title>AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS OF SINGLE AND MULTIPLE INTRAVENOUS DOSES OF PANTOPRAZOLE IN TWO AGE COHORTS OF HOSPITALIZED PEDIATRIC SUBJECTS 1 TO 16 YEARS OF AGE WHO ARE CANDIDATES FOR ACID SUPPRESSION THERAPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the pharmacokinetics (PK) and safety of&#xD;
      intravenous (IV) pantoprazole in patients 1 to 16 years old who are candidates for acid&#xD;
      suppression therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In hospitalized pediatric subjects, age 1 to 16 years who in the judgment of the investigator&#xD;
      are candidates for acid suppression therapy, the following are the objectives of this trial:&#xD;
&#xD;
      Primary Objectives To characterize the PK of single and multiple IV doses of pantoprazole in&#xD;
      pediatric subjects aged 1 to less than 2 years old.&#xD;
&#xD;
      To characterize the PK of single and multiple IV doses of pantoprazole in pediatric subjects&#xD;
      aged 2 to 16 years old.&#xD;
&#xD;
      Secondary Objectives To determine the safety, tolerability, and PK of single and multiple IV&#xD;
      doses of pantoprazole in each of the independent age cohorts.&#xD;
&#xD;
      To assess the CYP2C19 genotype in pediatric subjects receiving IV pantoprazole, to determine&#xD;
      the presence of the gene for the major enzyme responsible for metabolism of pantoprazole.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">May 18, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2027</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of distribution of IV pantoprazole</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of IV pantoprazole</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution of IV pantoprazole</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of IV pantoprazole</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CYP2C19 genotyping</measure>
    <time_frame>Day 1</time_frame>
    <description>CYP2C19 genotyping will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration-time profile from 0 to 24 hours</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration-time profile from 0 to 24 hours</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration-time profile from time 0 extrapolated to infinite time</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration-time profile from time 0 extrapolated to infinite time</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>IV pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV pantoprazole</intervention_name>
    <description>Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight</description>
    <arm_group_label>IV pantoprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged 1 to 16 years who in the judgment of the investigator are candidates for&#xD;
             gastric acid suppression therapy (ie, those with a presumptive diagnosis of GERD, a&#xD;
             clinical diagnosis of suspected GERD, symptomatic GERD, or endoscopically proven GERD)&#xD;
             and whom the investigator judges would need to receive IV PPI therapy for at least 4&#xD;
             days.&#xD;
&#xD;
          -  Body weight &gt; 5th percentile for age.&#xD;
&#xD;
          -  Y-site or dedicated IV line for administration of pantoprazole sodium.&#xD;
&#xD;
          -  Expected survival for at least 30 days.&#xD;
&#xD;
          -  Fertile male and female subjects of childbearing potential at risk for pregnancy must&#xD;
             agree to use a highly effective method of contraception throughout the study and for&#xD;
             at least 28 days after the last dose of assigned treatment. Female subjects of&#xD;
             non-childbearing potential must be premenarchal, have undergone hysterectomy with&#xD;
             bilateral oophorectomy, have medically confirmed ovarian failure, or achieved&#xD;
             post-menopausal status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in other studies involving investigational drug(s) or treatment with an&#xD;
             investigational drug within 30 days or 5 half lives prior to study entry and/or during&#xD;
             study participation.&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             study results and, in the judgment of the investigator, would make the subject&#xD;
             inappropriate for entry into this study.&#xD;
&#xD;
          -  Pregnant females; breastfeeding females; fertile male subjects, and female subjects of&#xD;
             childbearing potential who are unwilling or unable to use a highly effective method of&#xD;
             contraception for the duration of the study and for at least 28 days after last dose&#xD;
             of investigational product.&#xD;
&#xD;
          -  Serum CK levels &gt;3x ULN.&#xD;
&#xD;
          -  Known history of HIV or clinical manifestations of AIDS.&#xD;
&#xD;
          -  Known hypersensitivity to PPIs or to any substituted benzimidazole or to any of the&#xD;
             excipients.&#xD;
&#xD;
          -  History of treatment with any PPI within 2 days (48 hours) before investigational&#xD;
             product dosing on Day 1.&#xD;
&#xD;
          -  Use of H2RAs, sucralfate, misoprostol, or prokinetic agents, and bismuth preparations&#xD;
             within 1 day (24 hours) before investigational product dosing on Day 1.&#xD;
&#xD;
          -  Any disorder requiring chronic (every day) use of warfarin, carbamazepine, or&#xD;
             phenytoin, methotrexate, atazanavir or nelfinavir, clopidogrel, and potent inhibitors&#xD;
             and inducers of CYP2C19.&#xD;
&#xD;
          -  Chronic (daily) use of glucocorticoids. Steroid inhalers and topical steroids may be&#xD;
             used.&#xD;
&#xD;
          -  Active malignancy of any type, or history of a malignancy (Subject with a history of&#xD;
             malignancies that have been surgically removed or eradicated by irradiation or&#xD;
             chemotherapy and who have no evidence of recurrence for at least 5 years before&#xD;
             Screening are acceptable).&#xD;
&#xD;
          -  ALT or BUN &gt;2.0 ULN or estimated creatinine &gt;1.5 X ULN for age or any other laboratory&#xD;
             abnormality considered by the Investigator to be clinically significant within 14 days&#xD;
             before Screening.&#xD;
&#xD;
          -  In the Investigator's opinion, a chronic condition (eg, diabetes, epilepsy), which is&#xD;
             either not stable or well controlled and may interfere with the conduct of the study.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin induced thrombocytopenia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Health Specialty Center Dallas Campus</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. Ignacio Pirovano</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1430</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Militar Central &quot;Cirujano Mayor Dr. Cosme Argerich&quot;</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1426BOS</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University clinical center of the Republic of Srpska</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JSC Evex Medical Corporation</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD Imedi Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zentralapotheke St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Trials - Dipartimento Pediatrico Universitario Ospedaliero Padiglione Salviati</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS-Ospedale Pediatrico Bambino Gesù Farmacia Ospedaliera</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital HIMA San Pablo Caguas</name>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children's Clinic</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for mother and child healthcare dr Vukan Cupic</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for Child and Youth Health Care of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodny ustav detskych chorob</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Komunalne pidpryiemstvo Dnipropetrovskyi spetsializovanyi klinichnyi medychnyi tsentr materi</name>
      <address>
        <city>Dnipro</city>
        <zip>49006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Komunalne nekomertsiine pidpryiemstvo Ivano-Frankivska oblasna dytiacha klinichna likarnia</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Komunalne nekomertsiine pidpryiemstvo &quot;Khersonska dytiacha oblasna klinichna likarnia&quot;</name>
      <address>
        <city>M. Kherson</city>
        <zip>73013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bosnia and Herzegovina</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B1791089</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 15, 2014</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>candidate for acid suppression therapy</keyword>
  <keyword>presumptive diagnosis of GERD</keyword>
  <keyword>clinical diagnosis of suspected GERD</keyword>
  <keyword>symptomatic GERD</keyword>
  <keyword>endoscopically proven GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

